跳轉至內容
Merck
全部照片(1)

重要文件

SML2524

Sigma-Aldrich

Fexinidazole

≥98% (HPLC)

同義詞:

1-methyl-2-[[4-(methylthio)phenoxy]methyl]-5-nitro-1H-imidazole, HOE 239

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C12H13N3O3S
CAS號碼:
分子量::
279.31
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

light yellow to dark brown

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

CN1C(COC2=CC=C(SC)C=C2)=NC=C1[N+]([O-])=O

生化/生理作用

Anti Trypanosoma, Leishmania agent.
Fexinidazole is a potent anti-Trypanosoma agent. Trypanosoma species human protozoan pathogens are responsible for sleeping sickness and Chagas disease. In vivo, fexinidazole is oxidized to sulfoxide and sulfone metabolites that are effective in blocking the progression of the parasitic disease visceral leishmaniasis. The mechanism of action appears to be by reductive activation via an NADH-dependent nitroreductase expressed by the parasites.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Marcel Kaiser et al.
Antimicrobial agents and chemotherapy, 55(12), 5602-5608 (2011-09-14)
Fexinidazole is a 5-nitroimidazole drug currently in clinical development for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei. The compound and its two principal metabolites, sulfoxide and
Victor Kande Betu Ku Mesu et al.
Lancet (London, England), 391(10116), 144-154 (2017-11-09)
Few therapeutic options are available to treat the late-stage of human African trypanosomiasis, a neglected tropical disease, caused by Trypanosoma brucei gambiense (g-HAT). The firstline treatment is a combination therapy of oral nifurtimox and intravenous eflornithine that needs to be
Alan H Fairlamb et al.
Current medicinal chemistry (2018-04-28)
Interest in nitroheterocyclic drugs for the treatment of infectious diseases has undergone a resurgence in recent years. Here we review the current status of monocyclic and bicyclic nitroheterocyclic compounds as existing or potential new treatments for visceral leishmaniasis, Chagas' disease

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務